Trial Profile
Phase II trial of VEGF [vascular endothelial growth factor] Trap [aflibercept] in patients with metastatic breast cancer previously treated with anthracycline and/or taxane.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 05 Jan 2011 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
- 05 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Mar 2008 Status changed from suspended to in progress, as reported by ClinicalTrials.gov.